REG - AstraZeneca PLC - AstraZeneca prices a $5bn bond offering

AstraZenecaAnnouncement

22/02/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240222:nRSV0127Ea&default-theme=true

RNS Number : 0127E  AstraZeneca PLC  22 February 2024

22 February 2024 07:00 GMT

 

AstraZeneca prices a $5bn bond offering

 

AstraZeneca PLC ("AstraZeneca") announces that its wholly owned subsidiary
AstraZeneca Finance LLC, priced a four tranche global bond offering totalling
$5bn on 21 February 2024. The offering is expected to close on 26 February
2024, subject to customary closing conditions. The transaction, which is a
global offering registered with the US Securities and Exchange Commission
("SEC"), consists of the following four tranches:

Notes issued by AstraZeneca Finance LLC and fully and unconditionally
guaranteed by AstraZeneca

·    $1.25bn of fixed rate notes with a coupon of 4.80%, maturing 26
February 2027;

·    $1.25bn of fixed rate notes with a coupon of 4.85%, maturing 26
February 2029;

·    $1.00bn of fixed rate notes with a coupon of 4.90%, maturing 26
February 2031; and

·    $1.50bn of fixed rate notes with a coupon of 5.00%, maturing 26
February 2034.

AstraZeneca expects to use the net proceeds of the offering for general
corporate purposes, which may include the refinancing of existing
indebtedness.

 

Barclays Capital Inc., Citigroup Global Markets Inc., Deutsche Bank Securities
Inc. and J.P. Morgan Securities LLC acted as joint book-running managers on
the transaction. In addition, and in line with our commitment to Inclusion
& Diversity, four inclusive and diverse firms acted as underwriters on the
transaction: Blaylock Van, LLC, Cabrera Capital Markets LLC, C.L. King &
Associates, Inc. and Stern Brothers & Co.

 

The notes will be issued under AstraZeneca's effective shelf registration
statement on Form F-3, which AstraZeneca and AstraZeneca Finance LLC filed
with the SEC on 24 May 2021. The offering is being made solely by means of the
prospectus contained within that shelf registration statement, along with a
prospectus supplement forming part of the effective registration statement,
which investors should read.

 

A copy of the prospectus supplement and accompanying prospectus relating to
the offering can be obtained by contacting Barclays Capital Inc. by telephone
at +1-888-603-5847; Citigroup Global Markets Inc. by telephone at
+1-800-831-9146; Deutsche Bank Securities Inc. toll-free at +1-800-503-4611;
or J.P. Morgan Securities LLC collect at +1-212-834-4533. Readers may also
download these documents for free by visiting the Electronic Data Gathering,
Analysis, and Retrieval (EDGAR) system on the SEC website at www.sec.gov
(http://www.sec.gov) .

 

This announcement shall not constitute an offer to sell or the solicitation of
an offer to buy the securities described herein, nor shall there be any sale
of these securities in any jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under the
securities laws of any such jurisdiction.

 

The bond issuance does not impact AstraZeneca's financial guidance for 2024.

 

 

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IODFFFELFDILFIS